Recent Finacing
Recent Raise
Aerium Therapeutics develops monoclonal antibodies and antiviral therapeutics targeting SARS‑CoV‑2 and future epidemic threats, advancing preclinical mAb candidates that neutralize Delta, Omicron, and multiple Omicron subvariants.
